KEXING BIOPHARM CO.(SH:688136) Cai Jing Wang·2025-10-30 07:25Core Insights - The company reported a significant increase in revenue and net profit for the third quarter of 2025, indicating strong financial performance driven by overseas sales and cost management efforts [1] Financial Performance - The company's total revenue for the first three quarters reached 1.15 billion yuan, a year-on-year increase of 10.5% [1] - The net profit attributable to shareholders was 111 million yuan, up 547.7% year-on-year [1] - The net profit excluding non-recurring items was 70.45 million yuan, reflecting a year-on-year increase of 190.6% [1] - The operating cash flow showed a net outflow of 7.26 million yuan, a decline of 113.6% compared to the previous year [1] - The earnings per share (EPS) on a fully diluted basis was 0.5528 yuan [1] Quarterly Highlights - In the third quarter alone, the company achieved revenue of 447 million yuan, marking a substantial year-on-year increase of 60.6% [1] - The net profit for the third quarter was 30.92 million yuan, which is an increase of 483.3% year-on-year [1] - The net profit excluding non-recurring items for the third quarter was 25.17 million yuan, showing an impressive year-on-year growth of 829.5% [1] - The EPS for the third quarter was reported at 0.1536 yuan [1] Growth Drivers - The significant growth in net profit for the year-to-date period is attributed to increased sales in the EU market, which boosted overseas revenue [1] - The company has been actively managing costs in the marketing sector, leading to a reduction in sales expenses [1] - Non-recurring gains from the disposal of subsidiaries and changes in the fair value of private equity funds contributed to the increase in net profit [1]